Challenges in conducting clinical trials in children: approaches for improving performance

References

• Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin. Pharmacol. Ther.81, 477–479 (2007).
   Google Scholar
• Saint-Raymond A. Straight talk with ... Agnes Saint Raymond. Interview by Genevive Bjorn. Nat. Med.15, 354–355 (2009).
   Google Scholar
• Saint-Raymond A, Seigneuret N. The European paediatric initiative: 1 year of experience. Paediatr. Drugs11, 9–10 (2009).
   Google Scholar
• Stanski DR, Orloff JJ. Communicating with the FDA: the ‘third rail’ of a new model for drug development. J. Clin. Pharmacol.48, 144–145 (2008).
   Google Scholar
• Baer GR, Nelson RM. Ethical challenges in neonatal research: summary report of the ethics group of the newborn drug development initiative. Clin. Ther.28, 1399–1407 (2006).
   Google Scholar
• Altavilla A, Giaquinto C, Ceci A. European survey on ethical and legal framework of clinical trials in paediatrics: results and perspectives. J. Int. Bioethique19, 17–48, 121–122 (2008).
   Google Scholar
• EMEA. Ethical Considerations for Clinical Trials on Medicinal Products Conducted With the Paediatric Population. European Medicines Association, London, UK (2008).
   Google Scholar
• Chappuy H, Doz F, Blanche S, Gentet JC, Pons G, Treluyer JM. Parental consent in paediatric clinical research. Arch. Dis. Child.91, 112–116 (2006).
   PubMed Web of Science ®Google Scholar
• Amin SB, McDermott MP, Shamoo AE. Clinical trials of drugs used off-label in neonates: ethical issues and alternative study designs. Account Res.15, 168–187 (2008).
   PubMed Web of Science ®Google Scholar
• Chalumeau M, Treluyer JM, Salanave B et al. Off label and unlicensed drug use among French office based paediatricians. Arch. Dis. Child.83, 502–505 (2000).
   PubMed Web of Science ®Google Scholar
• Kimland E, Bergman U, Lindemalm S, Bottiger Y. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur. J. Pediatr.166, 527–532 (2007).
   Google Scholar
• Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin. Drug Saf.5, 703–718 (2006).
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349, 1157–1167 (2003).
   PubMed Web of Science ®Google Scholar
• L’Homme R, Warris A, Gibb D, Burger D. Children with HIV are not small adults: what is different in pharmacology? Curr. Opin. HIV AIDS2, 405–409 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet.45, 931–956 (2006).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Tucker GT, Rostami-Hodjegan A. Development of CYP2D6 and CYP3A4 in the first year of life. Clin. Pharmacol. Ther.83, 670–671 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl.11, 1481–1493 (2005).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Tucker C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr. Blood Cancer49, 928–940 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Tanner MS, Tucker GT. Developmental changes in the expression of enterocytic and hepatic cytochromes P4501A in rat. Xenobiotica32, 595–604 (2002).
   PubMed Web of Science ®Google Scholar
• Mahmood I, Green MD, Fisher JE. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J. Clin. Pharmacol.43, 692–697 (2003).
   PubMed Web of Science ®Google Scholar
• Rakhmanina NY, van den Anker JN. Pharmacological research in pediatrics: from neonates to adolescents. Adv. Drug Deliv. Rev.58, 4–14 (2006).
   PubMed Web of Science ®Google Scholar
• Kern SE, Stanski DR. Pharmacokinetics and pharmacodynamics of intravenously administered anesthetic drugs: concepts and lessons for drug development. Clin. Pharmacol. Ther.84, 153–157 (2008).
   Google Scholar
• Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL. Developing paediatric medicines: identifying the needs and recognizing the challenges. J. Pharm. Pharmacol.59, 1043–1055 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson TN. The problems in scaling adult drug doses to children. Arch. Dis. Child.93, 207–211 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur. J. Pediatr.165, 741–746 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr.165, 819–829 (2006).
   PubMed Web of Science ®Google Scholar
• Mahmood I. A Bayesian approach for the estimation of pharmacokinetic parameters in children. Am. J. Ther.10, 88–92 (2003).
   Google Scholar
• Mahmood I, Tammara V. A comparison of two sparse sampling population pharmacokinetic approaches for the estimation of pharmacokinetic parameters in children. Int. J. Clin. Pharmacol. Ther.42, 240–245 (2004).
   Google Scholar
• Meibohm B, Laer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J.7, E475–E487 (2005).
   PubMed Web of Science ®Google Scholar
• Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet.47, 231–243 (2008).
   PubMed Web of Science ®Google Scholar
• Koren G, Kearns GL, Reed M, Pons G. Use of healthy children as volunteers in drug studies: the ethical debate. Clin. Pharmacol. Ther.73, 147–152 (2003).
   Google Scholar
• Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. Anal. Chem.81, 1557–1563 (2009).
   PubMed Web of Science ®Google Scholar
• Baker-Smith CM, Benjamin DK Jr, Grabowski HG et al. The economic returns of pediatric clinical trials of antihypertensive drugs. Am. Heart J.156, 682–688 (2008).
   Google Scholar
• Li JS, Eisenstein EL, Grabowski HG et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA297, 480–488 (2007).
   Web of Science ®Google Scholar
• Zajicek A. The National Institutes of Health and the Best Pharmaceuticals for Children Act. Paediatr. Drugs11, 45–47 (2009).
   PubMedGoogle Scholar
• Boots I, Sukhai RN, Klein RH et al. Stimulation programs for pediatric drug research – do children really benefit? Eur. J. Pediatr.166, 849–855 (2007).
   PubMedGoogle Scholar
• Grieve J, Tordoff J, Reith D, Norris P. Effect of the pediatric exclusivity provision on children’s access to medicines. Br. J. Clin. Pharmacol.59, 730–735 (2005).
   PubMed Web of Science ®Google Scholar
• Koren G, Rieder M, MacLeod SM. The global alliance for pediatric pharmacology: the future is here and now. Paediatr. Drugs11, 4–5 (2009).
   Google Scholar
• Wade KC, Wu D, Kaufman DA et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob. Agents Chemother.52, 4043–4049 (2008).
   PubMed Web of Science ®Google Scholar
• Smith PB, Benjamin DK Jr, Murphy MD et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics122, E628–E633 (2008).
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Murphy MD et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA296, 1266–1273 (2006).
   PubMed Web of Science ®Google Scholar
• Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med.5, E191 (2008).
   PubMed Web of Science ®Google Scholar
• Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol.49, 291–301 (2009).
   PubMed Web of Science ®Google Scholar
• Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med.59, 1–12 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol.48, 303–332 (2008).
   PubMed Web of Science ®Google Scholar
• Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet.45, 1013–1034 (2006).
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol.4, 1143–1152 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson TN. Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol.59, 663–669 (2005).
   PubMed Web of Science ®Google Scholar
• Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther. Drug Monit.29, 271–278 (2007).
   PubMed Web of Science ®Google Scholar
• Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J. Pharm. Sci.98(10), 3850–3861 (2009).
   PubMed Web of Science ®Google Scholar
• Garnett CE, Beasley N, Bhattaram VA et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol.48, 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Powell JR, Gobburu JV. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther.82, 97–102 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Y, Bhattaram AV, Jadhav PR et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004–2006. J. Clin. Pharmacol.48, 146–156 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med. Inform. Decis. Mak.8, 6 (2008).
   PubMedGoogle Scholar
• Pons G, Treluyer JM, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther. Drug Monit.24, 9–14 (2002).
   PubMed Web of Science ®Google Scholar
• Zuppa A, Vijayakumar S, Jayaraman B et al. An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system. J. Clin. Pharmacol.47, 1172–1180 (2007).
   Google Scholar
• Anand KJ, Anderson BJ, Holford NH et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth.101, 680–689 (2008).
   PubMed Web of Science ®Google Scholar
• Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth.92, 208–217 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet.24, 25–36 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson TN. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology192, 37–48 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J. Pediatr. Gastroenterol. Nutr.47, 3–10 (2008).
   PubMed Web of Science ®Google Scholar
• Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. Prediction of metabolic drug clearance in humans: in vitro–in vivo extrapolation vs allometric scaling. Xenobiotica36, 567–580 (2006).
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab.8, 676–684 (2007).
   PubMed Web of Science ®Google Scholar